8-K/A: Inotiv Reports Strong Q3 FY25 Revenue & EBITDA Growth

Inotiv, Inc. announced significantly improved third-quarter fiscal 2025 financial results, with revenue up 23.5% and Adjusted EBITDA soaring, alongside the conclusion of a key SEC investigation.

Summary

• Total revenue for Q3 FY2025 increased 23.5% to $130.7 million, up from $105.8 million in Q3 FY2024.
• Consolidated net loss for Q3 FY2025 improved to $17.6 million, or 13.5% of total revenue, compared to a $26.1 million loss, or 24.7% of total revenue, in Q3 FY2024.
• Adjusted EBITDA for Q3 FY2025 was $11.6 million, or 8.9% of total revenue, a significant increase from $0.1 million, or 0.1% of total revenue, in Q3 FY2024.
• Discovery and Safety Assessment (DSA) revenue increased 8.9% to $48.2 million in Q3 FY2025, with net awards up 25% year-over-year.
• Research Models & Services (RMS) revenue surged 34.1% to $82.5 million in Q3 FY2025, primarily driven by increased NHP-related product and service revenue.
• The SEC's Division of Enforcement concluded its investigation related to non-human primate importations and does not intend to recommend an enforcement action against the Company.
• Cash and cash equivalents stood at $6.2 million as of June 30, 2025, down from $21.4 million at September 30, 2024.
• Cash used in operating activities for YTD FY2025 was $24.8 million, compared to $4.4 million used in YTD FY2024.
• Total debt, net of debt issuance costs, was $396.5 million as of June 30, 2025, a slight increase from $393.3 million on September 30, 2024.
• The Company has requested a draw of $3.0 million on its $15.0 million revolving credit facility, which had no borrowings outstanding as of June 30, 2025.
• A $10.0 million accrual was recorded for securities class action and shareholder derivative lawsuits, with an expected full recovery under existing insurance policies.

Sentiment

Score: 7

Explanation: The filing indicates strong operational improvements with significant revenue growth and a substantial reduction in net loss and increase in Adjusted EBITDA. The resolution of the SEC investigation is a major positive. However, the declining cash balance and increased cash burn remain areas of concern, tempering the overall positive sentiment.

Positives

• Q3 FY2025 total revenue increased by 23.5% year-over-year to $130.7 million, indicating strong growth.
• Consolidated net loss significantly decreased from $26.1 million in Q3 FY2024 to $17.6 million in Q3 FY2025.
• Adjusted EBITDA saw a substantial improvement, rising from $0.1 million in Q3 FY2024 to $11.6 million in Q3 FY2025.
• RMS revenue grew by 34.1% in Q3 FY2025, primarily due to increased NHP-related product and service revenue.
• DSA net awards for Q3 FY2025 increased 25% year-over-year, following a 27% improvement in Q2, driven by integration and optimization investments.
• The SEC's Division of Enforcement concluded its investigation into NHP importations and will not recommend an enforcement action against the Company, removing a significant regulatory overhang.
• Operating loss decreased significantly from $20.8 million in Q3 FY2024 to $5.7 million in Q3 FY2025, largely due to improved RMS operating income.
• The Company expects to recover the full $10.0 million accrual for lawsuits under existing insurance policies.

Negatives

• Cash and cash equivalents decreased significantly to $6.2 million at June 30, 2025, from $21.4 million at September 30, 2024.
• Cash used in operating activities increased to $24.8 million for YTD FY2025, compared to $4.4 million for YTD FY2024, indicating higher cash burn.
• Total debt, net, slightly increased to $396.5 million at June 30, 2025, from $393.3 million at September 30, 2024.
• DSA backlog slightly decreased year-over-year to $134.3 million at June 30, 2025, from $139.4 million at June 30, 2024.

Risks

• Uncertainty regarding strategic plans and their successful execution.
• Fluctuations in demand for services and products, and trends in the industries served.
• Market and company-specific impacts related to non-human primate (NHP) supply and demand.
• Compliance with the Resolution Agreement and Plea Agreement with the U.S. Department of Justice, including associated costs and the compliance monitor.
• Ability to service outstanding indebtedness and comply with or regain compliance with financial covenants, particularly those in the Seventh Amendment to the Credit Agreement.
• Maintaining a sufficient cash position and ability to fund operations, capital expenditures, and satisfy obligations.
• Ability to manage recurring and unusual costs effectively.
• Successful execution and realization of expected benefits from restructuring and site optimization plans.
• Ability to effectively utilize expanded capacity or integrate future expansion/acquisition initiatives.
• Ability to develop and build necessary infrastructure and teams to manage growth and projects.
• Ability to retain and hire key talent in a competitive market.
• Ability to market services and products effectively under corporate and brand names.
• Ability to develop new services and products to meet market needs.
• Potential inability to negotiate amendments to the Credit Agreement or obtain waivers related to financial covenants.
• Uncertainty regarding the final outcome of litigation, including settlement terms and amounts payable or recoverable.
• Impact of macroeconomic factors, including tariffs, on business operations and financial performance.

Future Outlook

The Company anticipates continued progress towards its financial goals, with expectations for sustained revenue and margin improvements driven by ongoing integration, optimization, and strategic investments. Management remains focused on client satisfaction and operational efficiency to build a strong recurring client base.

Management Comments

• "During the third quarter of fiscal 2025, we continued to make progress towards the financial goals we outlined during our investor day in May."
• "We were pleased that revenue and margins improved over the second quarter, and the year over year quarterly revenue increase of 23.5% was in line with our expectations."
• "Much of this [DSA net awards growth] was driven by the benefits of the integration, optimization and start up investments we have implemented over the last two years."
• "Our Discovery, Medical Device, Biotherapeutics and Genetic Toxicology businesses have seen strong growth in quoting and awards over the last two quarters."
• "As we experience this growth in revenue and awards, we remain highly focused on client satisfaction and delivery of on-time, high quality products and services."
• "This quarters results demonstrate continued progress in the execution of our strategic plans. We look forward to our future and want to thank all of our employees, shareholders and partners for their support and trust."

Industry Context

Inotiv operates as a leading contract research organization (CRO) specializing in nonclinical and analytical drug discovery and development services, as well as research models. The strong growth in RMS revenue, particularly NHP-related products and services, indicates robust demand within the preclinical research sector. The increase in DSA awards, especially in specialized areas like biotherapeutics and medical devices, suggests the company is capitalizing on high-growth segments within the broader drug development industry. The resolution of the SEC investigation related to NHP importations removes a significant industry-specific regulatory concern that had impacted the sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Legal Proceedings

• The SEC's Division of Enforcement concluded its investigation related to non-human primate importations from Asia and does not intend to recommend an enforcement action against the Company.
• The Company and certain current and former directors and officers are defendants in a putative securities class action lawsuit and two consolidated shareholder derivative lawsuits.
• A $10.0 million accrual has been recorded for these lawsuits as of June 30, 2025, with a corresponding $10.0 million receivable, as the Company expects to recover the full amount under existing insurance policies.

Stakeholder Impact

• Shareholders: Positive impact from improved financial performance (reduced net loss, increased Adjusted EBITDA) and the resolution of the SEC investigation, which removes a significant regulatory risk. However, the declining cash balance and increased cash burn could be a concern.
• Employees: Continued operations and strategic growth initiatives suggest stability, though past restructuring costs indicate ongoing optimization efforts.
• Customers: Management's focus on client satisfaction, on-time delivery, and high-quality products/services aims to benefit customers and build recurring business.
• Creditors: Improved Adjusted EBITDA may enhance the Company's ability to service its debt, but the increased cash used in operations and the need to draw on the revolving credit facility highlight ongoing liquidity management.

Next Steps

• Management will host a conference call on August 6, 2025, at 4:30 pm ET to discuss the third fiscal quarter of 2025 results.
• Continue execution of strategic plans, including integration, optimization, and startup investments.
• Monitor operational data and client metrics to build a strong recurring client base.
• Final resolution of securities class action and shareholder derivative lawsuits, including negotiations and court approvals.

Key Dates

Recommendation

The filing reveals substantial operational improvements, including strong revenue growth (23.5% in Q3 FY25) and a significant turnaround in profitability metrics, with Adjusted EBITDA soaring from near zero to $11.6 million. The conclusion of the SEC investigation without enforcement action removes a major regulatory overhang that has weighed on the stock. While the cash position is tight and cash burn increased, the positive momentum in core business segments (DSA awards, RMS revenue) and the resolution of a key risk factor suggest the company is turning a corner. A seasoned investor would recognize the de-risking and operational leverage, making it an attractive buy for potential upside, despite the need for continued monitoring of liquidity.

Keywords

Contract Research Organization, CRO, Drug Discovery, Drug Development, Preclinical Services, Nonclinical Services, Research Models, Safety Assessment, Biotherapeutics, Genetic Toxicology, Medical Device Services, SEC Filing, Earnings Report, Financial Results